Lantern Pharma Inc (LTRN)

Dec 16, 2025

Lantern Pharma (NASDAQ:LTRN) Shares Down 6.4% – Should You Sell? - Defense World

Dec 16, 2025

Dec 14, 2025

Analyst Upgrade: Why Lantern Pharma Inc stock is rated strong buyTrade Entry Summary & Daily Chart Pattern Signals - moha.gov.vn

Dec 14, 2025

Dec 10, 2025

Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Daily Commercial

Dec 10, 2025

Dec 05, 2025

Lantern Pharma announces LP-184 clinical trial met all primary endpoints - MSN

Dec 05, 2025

Dec 04, 2025

Lantern Pharma (NASDAQ: LTRN) Details Encouraging LP-184 Phase 1a Results Showing Durable Disease Control in Advanced Solid Tumors - Digital Journal

Dec 04, 2025

Dec 04, 2025

Will Lantern Pharma Inc. stock benefit from automationTreasury Yields & AI Forecasted Stock Moves - Newser

Dec 04, 2025

Dec 04, 2025

Will Lantern Pharma Inc. stock rally after Fed decisionsPortfolio Return Report & Low Volatility Stock Suggestions - Newser

Dec 04, 2025

Dec 03, 2025

Lantern’s cancer drug LP-184 shows promise in phase 1a trial - Investing.com Australia

Dec 03, 2025

Dec 03, 2025

Lantern Pharma advances AI-Driven cancer drug after successful Phase 1a trial - Proactive financial news

Dec 03, 2025

Dec 03, 2025

Lantern Pharma (LTRN) Advances with Promising Clinical Insights from Phase 1a Study - GuruFocus

Dec 03, 2025

Dec 03, 2025

Lantern Pharma reports additional positive LP-184 Phase 1a results showing durable disease control in heavily pre-treated advanced cancer patients - marketscreener.com

Dec 03, 2025

Dec 03, 2025

Lantern’s cancer drug LP-184 shows promise in phase 1a trial By Investing.com - Investing.com South Africa

Dec 03, 2025

Dec 03, 2025

Lantern Pharma Reports Positive Phase 1a Data For LP-184 In Advanced Solid Tumors - Nasdaq

Dec 03, 2025

Dec 03, 2025

Lantern Pharma Inc. (LTRN) Rises 9.5% in Pre-market: Amid Routine Trading - Stocks Telegraph

Dec 03, 2025

Dec 03, 2025

Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials - Yahoo Finance

Dec 03, 2025

Nov 30, 2025

Can Jai Balaji Industries Limited Sustain EPS Growth Under Competitive PressureMorning Star Patterns & Zero-Cost Stock Research by Professionals - earlytimes.in

Nov 30, 2025

Nov 25, 2025

BIOS Capital Management LP Sells 131,757 Shares of Lantern Pharma Inc. $LTRN - Defense World

Nov 25, 2025

Nov 21, 2025

Is Lantern Pharma Inc. stock vulnerable to regulatory risksTrade Volume Report & Real-Time Chart Breakout Alerts - newser.com

Nov 21, 2025

Nov 21, 2025

Is Lantern Pharma Inc. stock oversold or undervaluedJuly 2025 News Drivers & Entry and Exit Point Strategies - newser.com

Nov 21, 2025

Nov 21, 2025

How Lantern Pharma Inc. stock reacts to global recession fearsMarket Activity Report & Reliable Volume Spike Alerts - newser.com

Nov 21, 2025

Nov 19, 2025

Can Lantern Pharma Inc. stock deliver consistent earnings growth2025 EndofYear Setup & Proven Capital Preservation Methods - newser.com

Nov 19, 2025

Nov 19, 2025

Is Lantern Pharma Inc. stock a buy before product launchesTrade Entry Summary & Daily Growth Stock Investment Tips - newser.com

Nov 19, 2025

Nov 19, 2025

How Lantern Pharma Inc. stock performs in weak economy2025 Winners & Losers & Real-Time Buy Signal Alerts - newser.com

Nov 19, 2025